Latest news with #SYNT-101
Yahoo
16-05-2025
- Health
- Yahoo
‘Gastric bypass pill' causes weight loss without side effects: Study
(NewsNation) — A daily pill could give patients the weight-loss benefits of gastric bypass surgery or drugs like Ozempic — with none of the negative side effects, according to a recent clinical trial. Researchers say the SYNT-101 pill, developed by Boston-based Syntis Bio, mimics the effects of gastric bypass surgery while preserving muscle mass better than GLP-1 drugs like Ozempic, Wegovy and Mounjaro. The pill forms a film on the small intestine that redirects nutrient exposure to the lower intestine and gives patients a feeling of fullness — effectively mimicking gastric bypass surgery, which reroutes a person's intestines. The coating lasts up to 24 hours before it's expelled from the body. Who is eligible for weight loss medication? 'A lot remains to be seen with these medications, but the studies that we've seen so far look really promising,' said Dr. Jessica Duncan, an obesity medicine physician. The pill led to consistent weight loss and maintained lean muscle mass in rodent trials, and the first human study confirmed the pill formed a film and was safely cleared from the body within a day. 'These data further validate the potential of SYNT-101 as a convenient once-daily oral alternative or complement to GLP-1 drugs, which often involve substantial costs, severe side effects such as muscle loss and long-term maintenance issues despite high efficacy rates,' said Rahul Dhanda, CEO of Syntis, in a statement. Are weight loss drugs safe? Learn some of the side effects The study has limitations. The human trial only examined effects on nine patients who took one dose. Patients included seven women and two men between 24 and 53 who were not considered obese. 'So in that small group of people, they had no side effects, no serious or adverse events, and they didn't have any gastrointestinal side effects,' Duncan said. 'But with nine people, it's really hard to tell.' Duncan said the pill's safety profile will be developed in upcoming clinical trials. She told NewsNation that, whether weight loss is coming from a pill, surgery or injection, it's important to preserve muscle mass and eat well. 'Medications are super helpful for correcting the biological causes of obesity, but you have to make those lifestyle changes as well,' Duncan added. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
New York Post
14-05-2025
- Health
- New York Post
New daily ‘gastric bypass pill' leads to consistent weight loss — and no side effects: study
A new once-daily pill may raise the bar for weight loss meds. Ozempic, Mounjaro and similar drugs that mimic the GLP-1 hormone the body naturally produces after eating can cause significant weight loss, but a potential side effect is loss of lean muscle mass. The makers of the experimental drug SYNT-101 claim it mimics the effects of gastric bypass surgery while preserving lean muscle mass better than GLP-1 drugs. 3 SYNT-101 is a once-daily pill designed to mimic the effects of gastric bypass surgery while preserving lean muscle mass better than other weight loss drugs. New Africa – 'We believe that SYNT-101 will provide a convenient, more sustainable oral alternative and/or complement to systemic therapies such as GLP-1 drugs,' said Rahul Dhanda, CEO of Syntis Bio, the Boston-based biopharmaceutical company developing the treatment. SYNT-101 forms a synthetic film on the surface of the small intestine, shifting nutrient exposure to the lower intestine to promote a feeling of fullness. The lining is designed to work for up to 24 hours before it's naturally cleared from the body. In a new first-in-human study, seven women and two men between the ages of 24 and 53, who were not considered obese, took varying doses of SYNT-101 in liquid form. Imaging confirmed that the coating formed across the upper small intestine, and tissue samples showed that SYNT-101 was safely expelled within 24 hours. Further testing showed the participants had normal liver functioning and lower glucose absorption. SYNT-101 promotes better energy balance, Dhanda said, lessening the body's tendency to break down muscle tissue for fuel. 3 In rodent studies, SYNT-101 produced weight loss of 1% a week for six weeks while preserving 100% of lean muscle mass. íÅ¡í¸íâ¬í¸í»í» í íâ¹í¶í¾í² – No serious side effects were reported. Nausea is one of the most frequently reported side effects of GLP-1 drugs — and one of the major reasons why some users quit taking them. Hair loss and skin pain are among the less common side effects. Blindness and behavioral changes can occur in very rare cases. Weight loss was not tracked for this study, but the researchers said the results reflected reduced food consumption. In rodent studies, SYNT-101 produced weight loss of 1% a week for six weeks while preserving 100% of lean muscle mass. 3 While drugs that mimic the GLP-1 hormone the body naturally produces after eating can cause significant weight loss, a potential side effect is loss of lean muscle mass. Chanakon – The new findings were presented this week at the European Congress on Obesity in Malaga, Spain. 'The millions of people living with obesity need novel treatment options that are safe, effective and avoid the high costs and severe side effects that often accompany available treatment options,' Dhanda said. More research is needed to fully assess the drug's efficacy and safety. Syntis Bio plans to submit an Investigational New Drug (IND) application to the Food and Drug Administration later this year. 'We are eager to replicate these data in our upcoming Phase 1 clinical trial and further explore the ability of SYNT-101 to produce sustainable, safe, effective weight loss by reducing fat, preserving lean muscle and stimulating natural production of satiety hormones to prevent weight regain,' Dhanda said.
Daily Mirror
13-05-2025
- Health
- Daily Mirror
'Gastric bypass in a pill' helps weight loss without side effects, inventors say
Obesity conference hears how daily pill causes food digestion to bypass part of the stomach so fewer calories are actually absorbed by the body A 'gastric bypass in a pill' could help dieters feel full quicker and shed pounds, inventors say. The new daily tablet produces a coating at the top of the intestine, moving digestion to the lower part where fullness hormones are triggered. Manufacturer Syntis Bio reckons it could become 'the go to drug for weight management' as it will have fewer side effects than powerful appetite-suppressing injections. Gastric bypass operations have been performed by the NHS on the dangerously obese for over 20 years. They involve creating a small stomach pouch and directly connecting it to the small intestine, bypassing the rest of the stomach and the upper part of the small intestine. This reduces the body's ability to absorb calories and causes the release of key hormones. A new study, presented at the European Obesity Congress in Malaga, Spain, trialled a pill which works in the same way. It activates an enzyme in the gut to create a temporary coating in the top part of the intestine. Food cannot be absorbed through the coating and it directs it to lower parts of the intestines. Participants feel full before they have absorbed much of the food, so eat less. Researcher Rahul Dhanda, president of Syntis Bio, said: 'We make this to restrict absorption in the top part of the intestine, while the lower part of the intestine remains fully functional and unobstructed. The intestine is two to three metres long and this covers roughly 15cm at the top of it. It's about directing absorption to the lower intestine.' Glucose tolerance tests revealed delayed uptake of glucose and at 30 and 60 minutes, glucose absorption was far lower than in untreated patients. This delay suggests that absorption occurs later in the intestine, as expected, rather than in the coated region of the duodenum. The pilot study was not designed to measure weight loss, but participants receiving a full dose of the pill, currently called SYNT-101, also received blood tests to look at hormones linked to feelings of fullness. They showed elevated levels of leptin and lower levels of ghrelin, consistent with reduced food intake. The early stage trial suggested the drug is safe and the manufacturers believe it will come with fewer, if any, side effects when compared to weight loss injections. However more trials are needed to prove this and if it brings about sustained weight loss. Mr Dhanda said: 'What this does is integrate with the mucosal membrane which is naturally excreted by the body, and this goes along with it. You take the pill once a day in the morning and it should be cleared by the next morning or evening, depending on the patient. 'I anticipate the side effects to be minimal to none, and we haven't seen any yet in human tests. That is because we're not entering the bloodstream like injections do. It's a mechanical molecule so it's like we're inserting a stent, as opposed to a drug that is acting with the target and also off the target.'
Yahoo
10-04-2025
- Business
- Yahoo
Syntis Bio Releases New Data Supporting Potential of SYNT-101 as a Once-Daily Oral Treatment for Obesity at European Congress on Obesity and Weight Management
First-in-human data with investigational formulation of SYNT-101 establish preliminary safety, tolerability and efficacy markers, including modulation of hunger hormones Preclinical weight loss data demonstrate 100% preservation of lean muscle mass and significant reduction in weight and caloric consumption Findings support company's plan for submission of a U.S. IND application in H2 2025 BOSTON, April 10, 2025--(BUSINESS WIRE)--Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, today announced positive preclinical and first-in-human data for its lead candidate, SYNT-101, an investigational once-daily oral treatment for obesity. The data are being presented today during two scientific sessions at the European Congress on Obesity and Weight Management (Obesity 2025) in Barcelona. SYNT-101 is designed to induce metabolic changes that support improved glycemic control, weight loss and energy balance by redirecting nutrient absorption from the proximal to distal small intestine, creating a similar effect to gastric bypass. In preclinical rodent models, SYNT-101 produced consistent 1% weekly weight loss over the six-week study period while preserving 100% of lean muscle mass. In a first-in-human pilot study, an investigational formulation of SYNT-101 demonstrated strong evidence of nutrient redirection and resulting satiety hormone modulation. Importantly, SYNT-101 displayed strong safety and tolerability across both studies, with no adverse events reported. "These data further validate the potential of SYNT-101 as a convenient once-daily oral alternative or complement to GLP-1 drugs, which often involve substantial costs, severe side effects such as muscle loss and long-term maintenance issues despite high efficacy rates," said Rahul Dhanda, chief executive officer of Syntis. "With SYNT-101, we believe we can deliver sustainable, safe, effective weight loss by reducing fat while preserving lean muscle and stimulating natural production of satiety hormones, including GLP-1, to prevent weight regain. We are excited to replicate and expand upon these promising data in our upcoming Phase 1 clinical trial." Obesity 2025 Data Presentations The first presentation, "SYNT-101 first-in-human evaluation of a novel pharmacologic therapeutic to replicate gastric bypass for management of obesity," summarizes data from a nine-person safety and tolerability study of the drug at three dose levels. No treatment-related adverse events were reported, and all biopsy samples showed normal tissue histology. Glucose tolerance testing confirmed effective nutrient diversion, with no changes in safety biomarkers and complete clearance within 24 hours. Additionally, participants demonstrated favorable acute postprandial shifts in appetite-regulating hormones, including increased leptin and decreased ghrelin, consistent with enhanced satiety signaling and metabolic regulation. The company also discussed data from a six-week study of diet-induced obesity rodent models in a second presentation, "Preclinical evaluation of SYNT-101: effects on glycemic control, weight loss, and body composition in obese rodents." Following daily dosing and compared to control rodents, the test subjects experienced a total average weight loss of 6.1% (1% per week), 10% reduction in caloric consumption and 8% decrease in fasting glucose levels. Notably, lean muscle mass was fully preserved throughout the study, and no adverse events were observed. "The safety profile that SYNT-101 has shown to date, coupled with these data demonstrating preservation of lean muscle mass, is remarkable and an important advance in today's obesity treatment landscape," commented Louis Aronne, M.D., obesity expert, past president of The Obesity Society, and member of the Syntis clinical advisory board. "A major pitfall of current GLP-1 drugs is related to the gastrointestinal side effects as well as the loss of lean muscle that accompanies weight loss. Based on these data, SYNT-101's mechanism of action may avoid these issues entirely, which could provide both an alternative and adjunct for the millions of people living with obesity." About SYNT-101 SYNT-101 is being developed as a once-daily pill for the treatment of obesity. It works by transiently blocking nutrient absorption in the duodenum, the upper part of the small intestine, and redirecting nutrients to the distal small intestine to stimulate the natural secretion of satiety and metabolism-regulating hormones, including GLP-1. This mechanism, known as duodenal nutrient exclusion, is a key contributor to the efficacy of gastric bypass surgery, which remains the gold standard for weight loss and metabolic disease management. SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining), an oral formulation that establishes a safe, transient polymer coating to the duodenum. Syntis plans to submit an investigational new drug (IND) application to the U.S. FDA in H2 2025. About Syntis Bio Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world's most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body's nexus for metabolic control, digestion and drug absorption. Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders. Syntis is headquartered in Boston, MA. For more information, please visit and follow on LinkedIn. View source version on Contacts Media Contact: Dan Budwick, 1ABdan@ Investor Contact: IR@ Sign in to access your portfolio
